XM không cung cấp dịch vụ cho cư dân của Mỹ.
R
R

Regeneron


Tin tức

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Sept 16 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. REXEL RXL.PA : QXO QXO.O , the company billionaire Brad Jacobs is seeking to launch into building services, recently made an offer of around $9.4 billion to acquire Rexel RXL.PA that the French company on Sunday said it had rebuffed .
R
R
S
F
N
U

US FDA approves Eli Lilly's drug for eczema

UPDATE 2-US FDA approves Eli Lilly's drug for eczema Adds details on disease in paragraph 3, patient population in paragraph 6, other treatments in paragraphs 7-8, details on drug in paragraphs 8-9 Sept 13 (Reuters) - Eli Lilly LLY.N said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old.
P
R
S

Regeneron and Sanofi win another U.S regulatory approval for their Dupixent product

BRIEF-Regeneron and Sanofi win another U.S regulatory approval for their Dupixent product Sept 13 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O /SANOFI SASY.PA : DUPIXENT® (DUPILUMAB) APPROVED IN THE U.S. AS FIRST AND ONLY TREATMENT FOR ADOLESCENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP) Regeneron Pharmaceuticals and Sanofi today announced that the U.S.
R
S

Sanofi: Dupixent Meets Primary Endpoints In ADEPT pivotal study in BP

BRIEF-Sanofi: Dupixent Meets Primary Endpoints In ADEPT pivotal study in BP Sept 11 (Reuters) - Sanofi SA SASY.PA : DUPIXENT IS THE FIRST AND ONLY BIOLOGIC TO ACHIEVE SIGNIFICANT IMPROVEMENTS IN DISEASE REMISSION AND SYMPTOMS IN BULLOUS PEMPHIGOID POSITIVE PIVOTAL STUDY STUDY MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN ADULTS WITH MODERATE-TO-SEVERE DISEASE FIVE TIMES MORE PATIENTS ACHIEVED SUSTAINED DISEASE REMISSION WITH DUPIXENT THAN PLACEBO STUDY WILL SUPPORT REGULATORY SUBMISSIONS AROUND
R
S

U.S. Exlservice Holdings, Steel Dynamics, US Steel

U.S. RESEARCH ROUNDUP-Exlservice Holdings, Steel Dynamics, US Steel Sept 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Exlservice Holdings, Steel Dynamics and U.S. Steel Corp, on Monday. HIGHLIGHTS * Essex Property Trust Inc ESS.N : BMO raises target price to $310 from $294 * Exlservice Holdings Inc EXLS.O : Jefferies raises to buy from hold * Steel Dynamics Inc STLD.O : JP Morgan raises to neutral from underweig
C
R
S
U
E
U
C
C
H
U

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +3.2% Dollar Tree Inc DLTR.OQ +2.3% Amazon.com Inc AMZN.OQ +2.1% Comcast Corp CMCSA.OQ +1.6% Arm Holdings PLC ARM.OQ +1.2% Bottom Performers Percent Change Copart Inc CPRT.OQ -7.1% Old Dominion Freight Line Inc ODFL.OQ -6.8% AstraZeneca PLC AZN.OQ -3.5% Vertex Pharmaceuticals Inc VRTX.OQ -3.1% Regeneron Pharmaceuticals Inc REGN.OQ -3.0% The Nasdaq 100 .NDX lost 9
A
A
C
R
T
V
D
U
C
O

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Arm Holdings PLC ARM.OQ +6.0% PDD Holdings Inc PDD.OQ +5.1% MongoDB Inc MDB.OQ +3.8% PayPal Holdings Inc PYPL.OQ +3.8% Atlassian Corp TEAM.OQ +3.7% Bottom Performers Percent Change Dollar Tree Inc DLTR.OQ -9.9% NVIDIA Corp NVDA.OQ -5.4% Warner Bros Discovery Inc WBD.OQ -2.8% Regeneron Pharmaceuticals Inc REGN.OQ -1.9% Copart Inc CPRT.OQ -1.5% The Nasdaq 100 .NDX gained 8.92 points
N
P
R
D
U
A
P
C

U.S. Advance Auto Parts, Chewy, Workday

U.S. RESEARCH ROUNDUP-Advance Auto Parts, Chewy, Workday Aug 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Advance Auto Parts, Chewy and Workday, on Friday. HIGHLIGHTS * Advance Auto Parts Inc AAP.N : JP Morgan cuts target price to $43 from $55 * Chewy CHWY.N : Piper Sandler raises to overweight from neutral * Intuit Inc INTU.O : Jefferies raises target price to $790 from $770 * Williams-Sonoma Inc WSM.N : TD Co
A
A
A
B
I
J
N
N
R
R
H
A

US FDA declines to approve Regeneron's blood cancer therapy

UPDATE 1-US FDA declines to approve Regeneron's blood cancer therapy Adds details from paragraph 2 onward Aug 20 (Reuters) - The U.S. Food and Drug Administration has declined to approve Regeneron's REGN.O therapy for a common form of blood cancer, the company said on Tuesday. Regeneron was seeking regulatory approval of its therapy, linvoseltamab, in patients with multiple myeloma whose cancer has returned or worsened after at least three prior lines of treatment.
R

US FDA declines to approve Regeneron's blood cancer therapy

US FDA declines to approve Regeneron's blood cancer therapy Aug 20 (Reuters) - The U.S. Food and Drug Administration declined to approve Regeneron's REGN.O therapy for a common form of blood cancer, the company said on Tuesday. Reporting by Bhanvi Satija, Sneha S K and Nilutpal Timsina in Bengaluru; Editing by Shailesh Kuber
R

Regeneron Says FDA Issues Complete Response Letter For Co's Linvoseltamab

BRIEF-Regeneron Says FDA Issues Complete Response Letter For Co's Linvoseltamab Aug 20 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON PROVIDES UPDATE ON BIOLOGICS LICENSE APPLICATION FOR LINVOSELTAMAB REGENERON PHARMACEUTICALS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR REGENERON'S LINVOSELTAMAB REGENERON PHARMACEUTICALS INC - LINVO
R

Regeneron climbs on Q2 results beat

BUZZ-Regeneron climbs on Q2 results beat ** Drugmaker Regeneron's REGN.O shares rise ~1.8% to $1,098.47 ** Co reports Q2 adj. profit of $11.56/shr vs est. of $10.61/shr - LSEG data ** Posts quarterly revenue of $3.55 bln vs est. of $3.38 bln ** Stock up 25% YTD Reporting by Christy Santhosh
R

Regeneron Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Regeneron Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary Regeneron Pharmaceuticals Inc REGN.OQ reported quarterly adjusted earnings of $11.56​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $10.24. The mean expectation of twenty four analysts for the quarter was for earnings of $10.61 per share.
R

Regeneron beats quarterly results on strong demand for eczema, eye treatments

Regeneron beats quarterly results on strong demand for eczema, eye treatments Aug 1 (Reuters) - Drugmaker Regeneron Pharmaceuticals REGN.O exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs. The company has been upgrading patients who use its eye treatment, Eylea, to a higher-dose version to beat the impact from cheaper biosimilars available in the market and rival drugs.
B
R
R
S

Regeneron Q2 Adjusted EPS USD 11.56 Vs. IBES Estimate USD 10.6

BRIEF-Regeneron Q2 Adjusted EPS USD 11.56 Vs. IBES Estimate USD 10.6 Aug 01 (Reuters) - Regeneron Q2 EPS USD 12.41. Q2 revenue USD 3,550 million vs. IBES estimate USD 3,379 million outlook FY capex USD 750-820 million
R

Fed nods to cut, chips rebound, BoE up next

MORNING BID AMERICAS-Fed nods to cut, chips rebound, BoE up next A look at the day ahead in U.S. and global markets from Mike Dolan The Federal Reserve left Wall Street with little doubt about a first U.S. interest rate cut in seven weeks' time, but multiple cross-currents from the earnings season , Japan and China, and domestic politics all make for a noisy start to August.
A
A
A
B
C
G
I
N
R
U
X
M
J
U
U
U
F
E
W
A
M

Cencora raises annual profit forecast on strong demand for specialty medicines

Cencora raises annual profit forecast on strong demand for specialty medicines July 31 (Reuters) - Cencora COR.N raised its annual profit forecast again on Wednesday, driven by strong demand for high-priced specialty medicines that treat complex diseases such as cancer. The drug distributor also beat Wall Street estimates for third-quarter profit and revenue helped by strength in its U.S.
R

Regeneron Pharmaceuticals Inc <REGN.OQ> expected to post earnings of $10.61 a share - Earnings Preview

Regeneron Pharmaceuticals Inc expected to post earnings of $10.61 a share - Earnings Preview Regeneron Pharmaceuticals Inc REGN.OQ REGN.O is expected to show a rise in quarterly revenue when it reports results on August 1 for the period ending June 30 2024 The Tarrytown New York-based company is expected to report a 7.0% increase in revenue to $3.379 billion from $3.16 billion a year ago, according to the mean estimate from 22 analysts, based on LSEG data.
R

BioNTech rises after cancer therapy meets goal in mid-stage study

REFILE-BUZZ-BioNTech rises after cancer therapy meets goal in mid-stage study Corrects to add "$" sign in first bullet ** U.S. listed shares of BioNTech 22UAy.DE , BNTX.O rise 2.17% to $88.49 ** Co says its experimental mRNA cancer immunotherapy BNT111 in combination with Regeneron's REGN.O cancer drug Libtayo met the main goal in a mid-stage trial
P
R

Sanofi lifts 2024 profit forecast on strength in Dupixent, new products

UPDATE 2-Sanofi lifts 2024 profit forecast on strength in Dupixent, new products Adds share movement and analyst comment in paragraph 3, background on Roche and AstraZeneca in paragraph 4 By Manas Mishra July 25 (Reuters) - Sanofi SASY.PA on Thursday raised its full-year profit outlook after strong demand for blockbuster asthma drug Dupixent and better-than-expected sales of new launches helped its second-quarter results beat estimates.
A
R
S



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.